RT Journal Article
SR Electronic
T1 MUC1 Peptide Vaccination in Patients with Advanced Pancreas or Biliary Tract Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3575
OP 3579
VO 25
IS 5
A1 KOTARO YAMAMOTO
A1 TOMIO UENO
A1 TORU KAWAOKA
A1 SHOICHI HAZAMA
A1 MIKIKO FUKUI
A1 YUTAKA SUEHIRO
A1 YUICHIRO HAMANAKA
A1 YOSHITO IKEMATSU
A1 KOHZOH IMAI
A1 MASAAKI OKA
A1 YUJI HINODA
YR 2005
UL http://ar.iiarjournals.org/content/25/5/3575.abstract
AB Background: To evaluate the immunogenicity of MUC1 peptide vaccine in advanced pancreatic and bile duct cancers, a phase I clinical trial was conducted. Materials and Methods: A 100-mer MUC1 peptide consisting of the extracellular tandem repeat domain and incomplete Freund's adjuvant were subcutaneously administered to 6 pancreatic and 3 bile duct cancer patients at weeks 1, 3 and 5 and doses ranging from 300 to 3000 μg. Circulating intracytoplasmic cytokine-positive CD4+ T cells and anti-MUC1 IgG antibodies were measured before and after vaccination. Results: There were no adverse events, except for mild reddening and swelling at the vaccination site. In 8 patients eligible for clinical evaluation, 7 had progressive disease and 1 stable disease with a tendency for increased circulating anti-MUC1 IgG antibody after vaccination. Conclusion: This phase I clinical trial revealed the safety of a vaccine containing 100-mer MUC1 peptides and incomplete Freund's adjuvant. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved